Quantifying absolute benefit for adjuvant treatment options in renal cell carcinoma: A living interactive systematic review and network meta-analysis

This publication has 36 references indexed in Scilit:

• Randomized Phase III Trial of Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma
  Journal of Clinical Oncology, 2017
• Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after Nephrectomy
  New England Journal of Medicine, 2016
• Time to Reassess the Cancer Compendia for Off-label Drug Coverage in Oncology
  JAMA, 2016
• Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial
  The Lancet, 2016
• Ranking treatments in frequentist network meta-analysis works without resampling methods
  BMC Medical Research Methodology, 2015
• The PRISMA Extension Statement for Reporting of Systematic Reviews Incorporating Network Meta-analyses of Health Care Interventions: Checklist and Explanations
  Annals of Internal Medicine, 2015
• International Variations and Trends in Renal Cell Carcinoma Incidence and Mortality
  European Urology, 2015
• Continued Increase in Incidence of Renal Cell Carcinoma, Especially in Young Patients and High Grade Disease: United States 2001 to 2010
  Journal of Urology, 2014
• Features Associated with Recurrence Beyond 5 Years After Nephrectomy and Nephron-Sparing Surgery for Renal Cell Carcinoma: Development and Internal Validation of a Risk Model (PRELANE score) to Predict Late Recurrence Based on a Large Multicenter Database (CORONA/SATURN Project)
  European Urology, 2013
• Creating a Conversation: Insights from the Development of a Decision Aid
  PLOS Medicine, 2007